SCHEMBL22676427

SCHEMBL22676427

C=C(C)C(=O)Nc1ccc(-c2c(-c3ccc(Oc4ccc(F)cn4)c(F)c3)c3c(N)ncnc3n2C)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.73
▸ FGFR2 P21802 2/20 0.73
▸ FGFR4 P22455 2/20 0.73
▸ FGFR3 P22607 2/20 0.73
▸ CYP3A4 P08684 1/20 0.73
▸ CYP2D6 P10635 1/20 0.73
▸ CYP2C9 P11712 1/20 0.73
▸ CYP2C19 P33261 1/20 0.73
▸ MAPT P10636 1/20 0.39
▸ MET P08581 7/20 0.38
▸ BTK Q06187 4/20 0.37
▸ AXL P30530 2/20 0.36
▸ RAF1 P04049 3/20 0.36
▸ MAPK3 P27361 1/20 0.36
▸ KDR P35968 4/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ TEK Q02763 1/20 0.35
▸ P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30303900 1.00 FGFR1 (0.73) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303648 0.94 FGFR1 (0.65) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22677212 0.94 FGFR1 (0.65) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22676681 0.93 FGFR1 (0.64) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303558 0.93 FGFR1 (0.64) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22676429 0.92 FGFR1 (0.78) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303752 0.92 FGFR1 (0.78) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22676136 0.90 FGFR1 (0.77) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL30303681 0.90 FGFR1 (0.77) FGFR1FGFR2FGFR4FGFR3CYP3A4
SCHEMBL22675743 0.88 FGFR1 (0.80) FGFR1FGFR2FGFR4FGFR3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306529-A2 FGFR INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-01-17 — — EP disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF D.E. SHAW RESEARCH, LLC 2023-04-06 — — US disclosed
WO-2020231990-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2020-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR4 4/4885
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR4 4/4885
US-11780845-B2 FGFR inhibitors and methods of use thereof FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback